A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).

Trial Details

NCT ID
NCT07295951
Phase
PHASE1
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • 14C-bleximenib
  • bleximenib
Locations (sample)
  • Manchester, United Kingdom|53.48095,-2.23743

Key Eligibility Criteria

  • Body weight greater than or equal to (\>=) 40 kilograms (kg)
  • Relapsed or refractory (R/R) acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1 (NPM1), nucleoporin 98 (NUP98)…
  • Eastern cooperative oncology group (ECOG) performance status grade of 0 or 1
  • Regular bowel movements (that is \[i.e.\], average production of at least one stool every 2 days)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →